Abstract: Methods of treating a cancer or a tumor in a subject using a composition are provided. The composition includes a therapeutically effective amount of 2,4-disulfonyl a-phenyl tert-butyl nitrone (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount decreases a growth of the cancer or the tumor.

Abstract: A method of treating or preventing pruritus in a subject in need thereof using a pharmaceutical composition is provided. The method includes administering a therapeutically effective amount of T?4, T?4 fragments, T?4 isoforms, T?4 derivatives, or variants thereof, wherein the therapeutically effective amount decreases release of a pruritus-related factor or decreases release of an inflammatory cytokine from a target tissue is provided.

Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO:1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.

Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.

Abstract: The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.